Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.
Grace Baek, PharmD, BCOP
Advertisement
Articles by Grace Baek, PharmD, BCOP
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Opportunities for further optimization of CML management remain.
New agents can offer a more tailored approach to therapy selection.
Melanoma is responsible for 80% of skin cancer deaths.
New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.
Advertisement
Latest Updated Articles
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant SettingPublished: October 11th 2022 | Updated:
Navigating Drug Resistance in Chronic Myelocytic LeukemiaPublished: October 13th 2022 | Updated:
Pirtobrutinib and BTK Inhibitors in the CLL Treatment LandscapePublished: April 17th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
3
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
4
FDA Approves Gazyva for Active Lupus Nephritis
5
